Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily.

ABSTRACT: An important goal of effective rosacea treatment is to maximize the duration of remission. This was a two-part study. Part 1 was a multicenter, open-label, 12-week study in which adults with moderate or severe inflammatory lesions (papules and pustules) of rosacea received subantibiotic dose oral doxycycline 40 mg modified release (SDD₄₀ ) and topical metronidazole gel 1%. Part 2 was a multicenter, randomized, double-blind, placebo-controlled, 40-week study in which successfully treated subjects received once-daily SDD₄₀ or placebo capsules. The primary objective was to assess relapse and efficacy during long-term use of SDD₄₀ versus placebo. Relapse was defined as a return to baseline investigator global assessment (IGA) or lesion count, or any other neces

SUBMITTER: Del Rosso JQ 

PROVIDER: S-EPMC9285068 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature